Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Jones

Showing results (141-150 of 226) with videos related to

Pageof 23
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 22, 2009
Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cellsFederica Ferrigno, Danila Branca, Olaf Kinzel, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 3, 2016
Predicting long-term bleeding after percutaneous coronary interventionPraneet K Sharma, Adnan K Chhatriwalla, David J Cohen, et al.
Environmental Microbiology|July 5, 2006
Post-natal development of the porcine microbiota composition and activitiesSergey R Konstantinov, Ajay A Awati, Barbara A Williams, et al.
The Journal of Biological Chemistry|July 11, 2008
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domainMatthew J Bottomley, Paola Lo Surdo, Paolo Di Giovine, et al.
American Heart Journal|October 8, 2005
Monitoring clinical changes in patients with heart failure: a comparison of methodsJohn Spertus, Eric Peterson, Mark W Conard, et al.
Bioorganic & Medicinal Chemistry Letters|September 22, 2006
A series of novel, potent, and selective histone deacetylase inhibitorsPhilip Jones, Sergio Altamura, Prasun K Chakravarty, et al.
Cardiovascular Research|August 14, 2008
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failurePasquale Gallo, Michael V G Latronico, Paolo Gallo, et al.
Frontiers in Pharmacology|July 11, 2022
Screening of Hydrocarbon-Stapled Peptides for Inhibition of Calcium-Triggered ExocytosisYing Lai, Michael J Tuvim, Jeremy Leitz, et al.
Vascular Medicine (London, England)|October 12, 2019
Financial barriers in accessing medical care for peripheral artery disease are associated with delay of presentation and adverse health status outcomes in the United StatesQurat-Ul-Ain Jelani, Sunny Jhamnani, Erica S Spatz, et al.
Circulation. Cardiovascular Quality and Outcomes|May 13, 2018
Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)Zugui Zhang, Philip Jones, William S Weintraub, et al.
Pageof 23

Showing results (141-150 of 226) with videos related to

Sort By:
Pageof 23
Bioorganic & Medicinal Chemistry Letters|December 22, 2009
Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cellsFederica Ferrigno, Danila Branca, Olaf Kinzel, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 3, 2016
Predicting long-term bleeding after percutaneous coronary interventionPraneet K Sharma, Adnan K Chhatriwalla, David J Cohen, et al.
Environmental Microbiology|July 5, 2006
Post-natal development of the porcine microbiota composition and activitiesSergey R Konstantinov, Ajay A Awati, Barbara A Williams, et al.
The Journal of Biological Chemistry|July 11, 2008
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domainMatthew J Bottomley, Paola Lo Surdo, Paolo Di Giovine, et al.
American Heart Journal|October 8, 2005
Monitoring clinical changes in patients with heart failure: a comparison of methodsJohn Spertus, Eric Peterson, Mark W Conard, et al.
Bioorganic & Medicinal Chemistry Letters|September 22, 2006
A series of novel, potent, and selective histone deacetylase inhibitorsPhilip Jones, Sergio Altamura, Prasun K Chakravarty, et al.
Cardiovascular Research|August 14, 2008
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failurePasquale Gallo, Michael V G Latronico, Paolo Gallo, et al.
Frontiers in Pharmacology|July 11, 2022
Screening of Hydrocarbon-Stapled Peptides for Inhibition of Calcium-Triggered ExocytosisYing Lai, Michael J Tuvim, Jeremy Leitz, et al.
Vascular Medicine (London, England)|October 12, 2019
Financial barriers in accessing medical care for peripheral artery disease are associated with delay of presentation and adverse health status outcomes in the United StatesQurat-Ul-Ain Jelani, Sunny Jhamnani, Erica S Spatz, et al.
Circulation. Cardiovascular Quality and Outcomes|May 13, 2018
Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)Zugui Zhang, Philip Jones, William S Weintraub, et al.
Pageof 23